Addition of salmeterol to existing treatment in patients with COPD: a 12 month study (Q36183870)

12 August 2017

Addition of salmeterol to existing treatment in patients with COPD: a 12 month study (English)

1 reference

12 August 2017

R A Stockley

1 reference

12 August 2017

N Chopra

series ordinal

1 reference

12 August 2017

L Rice

series ordinal

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

12 August 2017

1 reference

12 August 2017

1 reference

12 August 2017

1 reference

12 August 2017

122-128

1 reference

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2104567

COPD exacerbations: the importance of a standard definition

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2104567

Quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2104567

Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2104567

Psychophysical bases of perceived exertion

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2104567

Ventilatory mechanics and expiratory flow limitation during exercise in patients with obstructive lung disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2104567

Development of a shuttle walking test of disability in patients with chronic airways obstruction

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2104567

The natural history of chronic airflow obstruction

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2104567

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2104567

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2104567

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2104567

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2104567

The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2104567

Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2104567

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2104567

In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2104567

Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2104567

Is lung function really a good parameter in evaluating the long-term effects of inhaled corticosteroids in COPD?

23 September 2018

1 reference

12 December 2020

A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire

1 reference

12 December 2020

Quality of life changes in COPD patients treated with salmeterol

1 reference

12 December 2020

Efficacy of salmeterol xinafoate in the treatment of COPD

1 reference

12 December 2020

Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium

1 reference

12 December 2020

Additive effects of salmeterol and fluticasone or theophylline in COPD

1 reference

12 December 2020

Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease

1 reference

12 December 2020

Identifiers

DOI

10.1136/THX.2004.033266

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

16443706

1 reference